Generate Biomedicines partners with Zealand Pharma on AI‑driven obesity drug platform
Generate Biomedicines and Zealand Pharma announced a strategic collaboration to create AI‑designed multispecific protein therapeutics for obesity and metabolic diseases. Generate will lead the research and receive $30 million upfront, up to $35 million in early pre‑clinical milestones, and eligibility for total milestones of nearly $1.2 billion, while Zealand will manage clinical development, regulatory filings and worldwide commercialization. The agreement also includes tiered royalties on future net sales and an option to add a third program.
Why it matters
Generate expects the upfront cash and milestone potential to fund its AI platform research and expand its pipeline, while the royalty structure could provide ongoing revenue if the candidates reach market. Zealand gains access to Generate’s generative‑AI technology to broaden its modality portfolio beyond peptides.
Key facts
- 1Generate will receive $30 million upfront under the collaboration. tradingview.com
- 2Generate can earn up to $35 million in early pre‑clinical milestones for the two initial programs. investing.com
- 3Total milestones available to Generate total nearly $1.2 billion, including development, regulatory and commercial milestones. investing.com
- 4Generate will lead research and candidate selection; Zealand will handle clinical development, regulatory submissions and worldwide commercialization. stocktitan.net
- 5The agreement includes tiered royalties on future worldwide net sales and an option to add a third program. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.